Incyte and SEQUENOM Announce Seminar Series "From Code to Cure - A Total Genotyping Solution" Palo Alto, CA and San Diego, CA, May 16, 2001 -- Incyte Genomics, Inc. (Nasdaq: INCY) and SEQUENOM™, Inc. (Nasdaq: SQNM) will hold three regional seminars to highlight the central role of Single Nucleotide Polymorphisms (SNPs) in genomics research. "From Code to Cure -- A Total Genotyping Solution," will be held May 22 in San Diego at the Torrey Pines Sheraton, May 23 at the West Coast Grand Hotel in Seattle, Washington and May 24 in Foster City, CA (Bay Area) at the Crowne Plaza Hotel. Each seminar will explore the identification and characterization of medically relevant SNPs, the current challenges facing researchers today and the value of the Incyte and SEQUENOM collaboration -- validated gene-based SNPs and an error-free high throughput genotyping platform. Incyte's in silico SNP Discovery technology, a proprietary algorithm to discover SNPs from Incyte's LifeSeq Gold sequence database, will be reviewed and the analysis of data generated from the Incyte-SEQUENOM collaboration will be presented. Incyte and SEQUENOM entered an agreement in October 2000 to generate the world's largest set of validated gene-based SNP assays. "Together, Incyte and SEQUENOM are pioneering the next phase of genomics," said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer. "This collaboration has already succeeded in setting new precedents in both its speed and its size, allowing genetic researchers worldwide to use information from Incyte's database to develop diagnostic and therapeutic applications based on the medical function of SNPs and genes." SEQUENOM offers a complete genotyping solution to determine the medical relevance of SNPs and genes. At the core of this technology is the MassARRAY™ system, a highly accurate and cost-effective platform for high throughput SNP analysis. The MassARRAY system is also the enabling platform used by SEQUENOM's Genomics business unit for identifying SNPs and genes that impact a significant portion of the population. "Our unique set of SNP data combined with SEQUENOM's cutting-edge technology will accelerate the drug discovery process and ultimately the time it takes to get new drugs to the market," said Roy A. Whitfield, CEO, Incyte Genomics. "These conferences are an ideal forum to share our knowledge and describe the highly successful collaboration between the two companies." To register for the conference or request more information, please contact Nicole Migdal at nmigdal@sequenom.com. SEQUENOM is leading a worldwide effort to identify genes and genetic variations with significant impact on human health. Using its innovative technologies, information and scientific strategy, the Company is rapidly translating data generated from the Human Genome Project into medically important applications. Breaking through the limitations of traditional research, SEQUENOM's MassARRAY technology, assay database, population genetics approach and ability to perform full genome screens are generating results that position SEQUENOM and its customers and collaborators to quickly capture novel leads to utilize in new genetics-based diagnostics, drugs and therapies. Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's Web site at www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the value of SNPs for use in genetics research, the use of SNPs by genetic researchers to understand the molecular basis for disease and individual response to medication and to develop diagnostic and therapeutic applications, the worldwide availability of validated SNP assays, the success of the collaboration and its contributions to genetic research, and the ability of this collaboration to accelerate drug discovery efforts, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including: the utilization of SNP assays in pharmaceutical and biotechnology research and development; the impact of technological advances and competition; changes in the business plans of Incyte and SEQUENOM; and other risks detailed from time to time in Incyte and SEQUENOM's SEC reports, including SEQUENOM's Annual Report on Form 10-K for the year ended December 31, 2000 and, with respect to Incyte, other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2001. These forward-looking statements speak only as of the date hereof. Incyte and SEQUENOM disclaim any intent or obligation to update these forward-looking statements.